NH&MRC Grant to support ‘Bird Flu’ Vaccine Project
22 February 2006, Melbourne: The Board of Directors of EQiTX Limited (ASX: EQX) announced today that Dr David Jackson, the Chief Scientist of its affiliated company VacTX Pty Ltd, and colleagues have been awarded a grant by the National Health and Medical Research Council under its call for urgent research into a potential avian influenza-induced pandemic. The grant is to develop a vaccine to avian influenza (‘bird flu’) using the VacTX proprietary lipopeptide vaccine technology.
The vaccine to be studied aims to provide broad protection against a range of different influenza isolates by stimulating a cellular response that destroys the virus in the lung before it can multiply enough to cause serious illness. This vaccine strategy is novel because it is expected that the immune response will be fully reactivated a few days after a vaccinated person is infected. This immune response would then help to clear lung cells infected with the influenza virus more quickly.
Dr Jackson said, ‘All of the available influenza vaccines rely on their ability to induce antibody to limit infection with influenza, but are rendered ineffective if the virus changes to a new version. The vaccine being investigated aims to program the body’s immune killer cells (cytotoxic T lymphocytes) to target parts of the virus that don’t change from one generation of virus to the next. We believe that these killer cells will be activated to clear the avian influenza virus before it reaches lethal levels and already have evidence in animals that this happens.’
The funded studies build upon the recently published findings of Dr Jackson and his colleagues that lipopeptide vaccines enhance the clearance of influenza virus from the lungs of vaccinated mice (Deliyannis G et al, Eur J Immunol 2006; http://dx.doi.org/10.1002/eji.200535217). The grant of $211,000 over a period of 18 months will fund laboratory and animal studies on the efficacy of a human avian influenza vaccine.
EQX Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)